tiprankstipranks
Trending News
More News >
Appili Therapeutics Inc Class A (TSE:APLI)
:APLI
Advertisement

Appili Therapeutics Inc Class A (APLI) AI Stock Analysis

Compare
25 Followers

Top Page

TS

Appili Therapeutics Inc Class A

(OTC:APLI)

Rating:47Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
Appili Therapeutics Inc Class A faces significant financial and valuation challenges, highlighted by persistent unprofitability and high leverage. While technical indicators show some potential for price movement, the stock is in a downtrend. Positive corporate events provide some hope for future growth, but the overall outlook remains cautious.

Appili Therapeutics Inc Class A (APLI) vs. iShares MSCI Canada ETF (EWC)

Appili Therapeutics Inc Class A Business Overview & Revenue Model

Company DescriptionAppili Therapeutics Inc Class A (APLI) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics targeting infectious diseases. The company operates in the healthcare sector and is dedicated to addressing significant unmet medical needs in the field of infectious disease treatment through its innovative pipeline of drug candidates.
How the Company Makes MoneyAppili Therapeutics Inc primarily generates revenue through the development and commercialization of its drug candidates. The company's revenue streams include milestone payments, royalties, and potential licensing agreements with pharmaceutical partners. Appili may also receive government grants or funding to support the research and development of its therapeutic products. Strategic partnerships and collaborations with other pharmaceutical companies play a crucial role in advancing its drug pipeline and securing financial resources necessary for clinical trials and commercialization efforts.

Appili Therapeutics Inc Class A Financial Statement Overview

Summary
Appili Therapeutics Inc Class A is facing substantial financial challenges, including consistent unprofitability, high leverage, and negative equity. Despite slight improvements in cash flow, the company's financial health is concerning, necessitating efforts to improve revenue generation and manage debt.
Income Statement
35
Negative
Appili Therapeutics Inc Class A has faced significant challenges in revenue generation, with a substantial decline of 87.86% in revenue from 2024 to 2025. The company has consistently reported negative net income and EBIT over the years, indicating persistent unprofitability. Gross profit margins remain at 100% due to revenue matching the cost, but the overall profitability is severely impacted by high operating losses.
Balance Sheet
25
Negative
The company exhibits high leverage with a negative stockholders' equity, resulting in an undefined debt-to-equity ratio. The equity ratio is also negative, reflecting more liabilities than assets. This financial instability poses significant risks to the company's sustainability and future operations.
Cash Flow
40
Negative
Appili has demonstrated some improvement in cash flow management with a positive operating cash flow in 2025. However, the free cash flow remains volatile, with a sharp negative trajectory in previous years. The operating cash flow to net income ratio is not favorable due to continuous negative net income, indicating challenges in converting revenue into cash.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue100.44K827.41K334.18K1.39M0.00
Gross Profit100.44K827.41K327.91K1.39M-14.84K
EBITDA360.57K-2.10M-8.19M-24.31M-14.87M
Net Income-2.62M-3.78M-9.24M-25.12M-14.33M
Balance Sheet
Total Assets3.03M1.49M3.13M8.28M18.32M
Cash, Cash Equivalents and Short-Term Investments1.23M94.49K2.47M6.66M16.12M
Total Debt12.29M8.18M7.67M4.98M1.03M
Total Liabilities16.43M12.42M10.53M11.55M5.56M
Stockholders Equity-13.40M-10.92M-7.40M-3.27M12.75M
Cash Flow
Free Cash Flow866.46K-2.49M-10.10M-19.08M-11.46M
Operating Cash Flow868.82K-2.46M-10.10M-19.08M-11.45M
Investing Cash Flow-2.36K-29.06K-3.17K5.06M-4.99M
Financing Cash Flow193.68K122.05K5.91M9.56M17.02M

Appili Therapeutics Inc Class A Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.02
Price Trends
50DMA
0.02
Negative
100DMA
0.03
Negative
200DMA
0.03
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
44.06
Neutral
STOCH
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APLI, the sentiment is Neutral. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.06 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:APLI.

Appili Therapeutics Inc Class A Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
47
Neutral
C$1.82M34.61%-86.89%30.77%
46
Neutral
C$195.87M-3.27-23.14%2.65%20.75%-0.36%
22
Underperform
C$9.27M45.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:APLI
Appili Therapeutics Inc Class A
0.02
-0.02
-57.14%
TSE:MRVL
Marvel Biosciences Corp
0.18
0.06
50.00%

Appili Therapeutics Inc Class A Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Appili Therapeutics Advances Infectious Disease Solutions with LIKMEZ Re-launch and Vaccine Developments
Positive
Jun 25, 2025

Appili Therapeutics has re-launched LIKMEZ, the first FDA-approved liquid oral suspension of metronidazole, in the U.S., addressing a significant gap for patients who have difficulty swallowing tablets. The company is also progressing with its ATI-1701 vaccine candidate for tularemia, supported by U.S. Air Force funding, and ATI-1801 for cutaneous leishmaniasis, with positive Phase 3 data. These developments highlight Appili’s strategic focus on infectious disease solutions and potential market impact.

Private Placements and FinancingM&A TransactionsBusiness Operations and Strategy
Appili Therapeutics Ends Agreement with Aditxt, Secures Loan Extensions
Neutral
May 30, 2025

Appili Therapeutics announced the formal termination of its arrangement agreement with Aditxt Inc., effective May 30, 2025. As a result, Appili is entitled to a termination fee of USD $1,000,000 from Aditxt. Additionally, Appili has secured three-month extensions on loans from Long Zone Holdings Inc. and Bloom Burton & Co. Inc., with repayment due by August 31, 2025. This termination and financial adjustments may impact Appili’s operations and financial positioning, but the company continues to focus on its mission to combat infectious diseases.

M&A TransactionsBusiness Operations and Strategy
Appili Therapeutics Faces Termination of Agreement with Aditxt
Negative
May 19, 2025

Appili Therapeutics announced that Aditxt, Inc. has issued a notice to terminate their arrangement agreement effective May 31, 2025. As a result, Appili is entitled to a termination fee of USD $1,000,000, which may impact the company’s financials and strategic positioning in the biopharmaceutical industry.

Product-Related AnnouncementsBusiness Operations and Strategy
Appili Therapeutics Advances Tularemia Vaccine Research
Positive
May 1, 2025

Appili Therapeutics announced the publication of a manuscript in Frontiers in Bacteriology, highlighting the potential of their biodefense vaccine, ATI-1701, in preventing tularemia outbreaks. The review consolidates recent findings on immune responses to Francisella tularensis, the pathogen causing tularemia, and suggests pathways for effective vaccine development. ATI-1701 is positioned as a potentially valuable vaccine due to the lack of approved vaccines for tularemia in major markets, emphasizing its importance as a biodefense priority globally.

Product-Related AnnouncementsBusiness Operations and Strategy
Appili Therapeutics Secures New Patents for LIKMEZ, Strengthening Market Position
Positive
Apr 28, 2025

Appili Therapeutics has announced the granting of new patents by the United States and Mexican patent offices for its oral formulation of metronidazole, LIKMEZ. These patents, which expire in 2039, enhance the protection of LIKMEZ by covering its unique taste-masked composition and therapeutic applications. This development is significant for Appili as it strengthens the company’s market position and supports the commercialization efforts of its partner, Saptalis Pharmaceuticals. The listing of the U.S. patent in the FDA’s Orange Book further solidifies the product’s market presence, with Saptalis planning a re-launch under its own label.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025